Navigation Links
Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Date:8/19/2007

Management to Make Two Presentations on the Topic of Drug Repurposing and

Indian Clinical Trial Strategy

MORRISTOWN, N.J., Aug. 16 /PRNewswire/ -- Vicus Therapeutics, Inc., an oncology-focused, clinical-stage biopharmaceutical company, announced today that Chief Executive Officer, John Maki, and Chief Scientific Officer, Frederic Young, Ph.D., will each present at the 234th American Chemical Society National Meeting on Sunday, August 19, 2007. The Meeting is being held at the Boston Convention & Exhibition Center in Boston, MA.

Dr. Young will present "Hypothesis-driven Drug Repurposing Based on a Novel Systems Biology Approach," including a discussion of Vicus' complexity theory-based drug repurposing approach in creating a pipeline of product candidates for the treatment of important unmet medical needs. The Company's approach can be applied to the discovery of product candidates for any indication, including cancer cachexia, a metabolic disorder, mucositis, a wound healing disorder, and cancer fatigue, a CNS disorder. The specific application of this method will be discussed in the context of the Company's lead compound, VT-122. Dr. Young's presentation is scheduled for 11:45 a.m.

Mr. Maki's presentation, entitled "Synergistic Advantages of Drug Repurposing and Clinical Trial Off-shoring in India", will include a discussion of the unique synergistic advantages of drug re-profiling and off- shoring, as well as an overview of the steps necessary to realize such advantages. Specifically, Mr. Maki will provide highlights from the Company's ongoing Phase 2 clinical trial of VT-122 for cancer cachexia, now being conducted in the U.S. and India. In addition, he will review recent changes by the Drug Controller General of India (DCGI, the Indian FDA-regulatory equivalent), Indian clinical research infrastructure, and the acceptance of Indian data by the U.S. Food & Drug Administration (FDA) that is currently driving the expl
'/>"/>

SOURCE Vicus Therapeutics

Copyright©2007 PR Newswire.

Page: 1 2 3

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
3. Wisconsin firms to present at Cleantech venture capital event
4. New Sonic Foundry search engine finds words, phrases in video presentations
5. Lone Wisconsin firm to present at InvestMidwest
6. Sonic Foundry creates search engine for 7,000 expert video presentations
7. InvestMidWest calls for business presentations
8. Wicab to present BrainPort at Boston conference
9. Three more Wisconsin firms to present at venture forum
10. Six Wisconsin firms to present at BIO Mid-America VentureForum
11. New Health and Human Services representative for Midwest
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Best Sanitizers, Inc., the first company ... sanitizer, asks food processors and food handling professionals to ... they’re currently using to Best Sanitizers’ Alpet® E3 ... to fighting cross-contamination and the spread of pathogens in ... are key criteria that make a hand sanitizer most ...
(Date:8/28/2014)... in spintronics, an electronic which is not only ... on their spin and the spin-related magnetism. Spin-charge ... signals and vice versa. Recently, the research group ... Physics at Johannes Gutenberg University Mainz in collaboration ... has for the first time realised a new, ...
(Date:8/28/2014)... executives from clinical trial marketing firm BBK Worldwide will lead ... Clinical Trials 2014 , to be held at the Hyatt ... Patient recruitment experts Bonnie A. Brescia , Matthew ... on the benefits of employing an effective patient engagement strategy, ... mobile apps – can be used to drive study participation ...
(Date:8/28/2014)... Aug. 28, 2014  Armetheon, Inc. ( www.armetheon.com ... mid- to late-stage cardiovascular drug candidates, today announced ... first round of financing. The Series A round ... Bioventures with participation from investors that included Atheneos ... Dr. Larry Hsu , the founder of ...
Breaking Biology Technology:Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3A new, tunable device for spintronics 2A new, tunable device for spintronics 3BBK Worldwide Leads Sessions at Key September Events 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
... , , , ... biotechnology company discovering and developing innovative treatments for pain, announced ... of physiology at the University of California, San Francisco, and ... Solace,s scientific advisory board. , , ...
... , , , SAN ... OREX ) today announced that its underwriters fully exercised their ... common stock in connection with its previously announced public offering ... shares purchased, the company sold 11,500,000 shares at a public ...
... PRINCETON, N.J., July 24 Serious buyers and sellers of ... gather at InformexUSA 2010 will experience even more focused, more efficient ... precisely with others in their specific market. , ... in San Francisco, with a new agenda to reflect a targeted, ...
Cached Biology Technology:Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board 2Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board 3Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters 2Informex Rebrands Into Separate Pharmaceutical and Specialty Chemical Segments to Better Serve Exhibitors and Attendees 2Informex Rebrands Into Separate Pharmaceutical and Specialty Chemical Segments to Better Serve Exhibitors and Attendees 3
(Date:9/1/2014)... BOSTON (September 1, 2014, 10:20 AM EDT) It ... healthy low-calorie foods over unhealthy higher-calorie foods, according to ... Human Nutrition Research Center on Aging (USDA HNRCA) at ... today in the journal Nutrition & Diabetes , ... suggests that it is possible to reverse the addictive ...
(Date:9/1/2014)... bats are perfectly adapted to a life without light. They ... echoes to measure distance to obstacles or prey. In their ... A study carried out by researchers at Technische Universitt Mnchen ... dynamically adapts to external factors. , Closer objects ... too close to an object, the number of activated neurons ...
(Date:8/31/2014)... a fast and accurate tool to diagnose tuberculosis ... newly developed test (TAM-TB assay) is the first ... children. The test features excellent specificity, a similar ... of a blood test. The promising findings are ... in children, particularly in tuberculosis-endemic regions. , The ...
Breaking Biology News(10 mins):Training your brain to prefer healthy foods 2Zooming in for a safe flight 2New tuberculosis blood test in children is reliable and highly specific 2
... turtles are too optimistic, according to Loren McClenachan ... McClenachan, Jeremy Jackson and Marah Newman agree ... helped increase green and hawksbill turtle populations that ... that dwindling turtle populations on many historically important ...
... population in New Hampshire's Great Bay estuary has plummeted by ... disease MSX. The previous century saw a slower but equally ... local extinction on some reefs," says Ray Grizzle, research associate ... , Now Grizzle is working to bring oysters back ...
... a surprisingly high percentage of people with type 1 ... years or longer (The Joslin Medalists) may still have ... The findings will be presented June 12 at the ... Washington, D.C. , "It is surprising that some ...
Cached Biology News:All the eggs in one basket 2All the eggs in one basket 3UNH researcher restoring oyster reefs to Great Bay 2Joslin discovers signs of residual islet cell function in people with long-term type 1 diabetes 2Joslin discovers signs of residual islet cell function in people with long-term type 1 diabetes 3
Rabbit polyclonal to Somatostatin 28 ( Abpromise for all tested applications). entrezGeneID: 6750 SwissProtID: P61278...
... Features Convenient platform for tube ... - 96 x 0.2ml V-bottom tubes ... Thermo-Tube Plates - Thermo-Fast® 96 Non-Skirted ... - 48 x 0.5ml Thermo-Tubes Multiple ...
... Pro upgrade for Shimadzu Phoretix 2D, Expression ... statistical tools for comparative gel analysis studies ... Data base add on component ... version 9i release 2 client software). ...
... systems provide linking and labelling reagents ... specific primary antibodies for visualising cellular ... accomplished using an ultra-sensitive indirect labelling ... technology. Secondary antibodies are polymerised directly ...
Biology Products: